Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis

Fabrizio De Benedetti, Hermine I. Brunner, Nicolino Ruperto, Andrew Kenwright, Stephen Wright, Inmaculada Calvo, Ruben Cuttica, Angelo Ravelli, Rayfel Schneider, Patricia Woo, Carine Wouters, Ricardo Xavier, Lawrence Zemel, Eileen Baildam, Ruben Burgos-Vargas, Pavla Dolezalova, Stella M. Garay, Rosa Merino, Rik Joos, Alexei GromNico Wulffraat, Zbigniew Zuber, Francesco Zulian, Daniel Lovell, Alberto Martini

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA; treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. METHODS: We randomly assigned 112 children, 2 to 17 years of age, with active systemic JIA (duration of ≥6 months and inadequate responses to nonsteroidal antiinflammatory drugs and glucocorticoids) to the anti-interleukin-6 receptor antibody tocilizumab (at a dose of 8 mg per kilogram of body weight if the weight was ≥30 kg or 12 mg per kilogram if the weight was

Original languageEnglish
Pages (from-to)2385-2395
Number of pages11
JournalNew England Journal of Medicine
Issue number25
Publication statusPublished - Dec 20 2012

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis'. Together they form a unique fingerprint.

Cite this